PodcastIntel
Sign in Get Started Free
HCPLive
HCPLive

Comparator Confounds in Psilocybin Trials, With Josh Woolley, MD, PhD

Sep 21, 2026 · 0:04:25
✨ AI Summary
  • Finding effective comparators for psilocybin trials is challenging.
  • Dextromethorphan (DXM) carries risk due to its antidepressant potential.
  • Josh Woolley, MD, PhD, explains the UMBRAA blinding framework.

Guests on This Episode

More from HCPLive

View all episodes →

Get AI Summaries for Every New Episode

Subscribe to HCPLive and get AI summaries, guest tracking, and email digests delivered automatically.

Sign Up Free →